Wilkinson Walsh Celebrates Banner Year of High Stakes Trial Wins By Next Generation Of Trial Lawyers

WASHINGTON – Wilkinson Walsh is racing into its fourth year after notching a series of high-profile victories, led by a large and diverse group of partners. In 2018, all of Wilkinson Walsh’s partners participated in trials and case-dispositive hearings, and several other attorneys achieved significant on-their-feet experience, including through pro bono cases. The firm earned repeated recognition for the depth and successes of its bench and added a new crop of talented litigators to its roster. Wilkinson Walsh won three trials in 2018, each of which was first-chaired by a different partner: On April 27, 2018, Wilkinson Walsh, led by Brian Stekloff, Jeremy Barber, and Lori McGill, won a unanimous defense verdict for Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals in Russell v. Janssen Pharmaceuticals, Inc., the second state-court Xarelto bellwether trial in the Pennsylvania Court of Common Pleas. On May 21, 2018, Wilkinson Walsh, led by Kosta Stojilkovic …

Wilkinson Walsh Wins Victory for Bayer in First State-Court Xarelto Trial

WASHINGTON – On January 9, 2018, Wilkinson Walsh, led by Founding Partners Beth Wilkinson and Alexandra Walsh, won the first state-court bellwether trial over the blood-thinner Xarelto when the trial court entered judgment for Bayer and Janssen notwithstanding a jury verdict in favor of the plaintiff.  Wilkinson and Wilkinson Walsh had previously secured two full defense verdicts for Bayer in similar cases in the federal multi-district litigation in Louisiana. In December 2017, a jury in the Philadelphia Court of Common Pleas awarded nearly $28 million to plaintiff Lynn Hartman in a lawsuit that alleged that Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals were liable for claims that the Xarelto label did not adequately instruct doctors on the risks of bleeding associated with the anticoagulant Xarelto.  Bayer and Janssen then filed motions for judgment notwithstanding the verdict and a new trial.  The motions raised two key points (among many others).  …